HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that a presentation of clinical trial data from the most recently completed clinical studies of NX-1207, the Company’s drug in development for benign prostatic hyperplasia (BPH) will be made by Dr. Pat Hezmall of Arlington, Texas at the 87th Annual Meeting of the South Central Section of the American Urological Association Meeting on September 18 in San Diego, California. The Nymox investigational drug has entered Phase 3 development.
